{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T13:10:15Z","timestamp":1779455415772,"version":"3.53.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism, is a major cardiovascular condition associated with substantial morbidity, mortality, and risk of recurrence. Extended anticoagulation is frequently required beyond the initial treatment phase, yet the optimal strategy remains uncertain. Direct oral anticoagulants (DOACs) provide practical advantages over vitamin K antagonists, but their role in long-term secondary prevention warrants clarification. We performed a systematic review and meta-analysis of placebo-controlled randomized controlled trials evaluating extended DOAC therapy in VTE. A comprehensive literature search identified 5 eligible trials with a total of 13,802 patients. Data were pooled using random-effects models to calculate risk ratios (RR) and 95% confidence intervals (CI). Outcomes included recurrent VTE, DVT, pulmonary embolism, mortality, stroke, cancer incidence, and bleeding events. Compared with placebo, extended DOAC therapy significantly reduced symptomatic recurrent VTE (RR, 0.26; 95% CI, 0.16\u20130.41), with consistent findings across sensitivity analyses. DOACs demonstrated strong protection against recurrent DVT, while results for recurrent pulmonary embolism were less consistent. No significant differences were observed in all-cause mortality, ischemic stroke, or cancer incidence. Safety analyses showed no increase in major bleeding. Extended DOAC therapy is highly effective in preventing recurrent VTE, particularly DVT, and maintains an acceptable safety profile. Despite the absence of mortality or stroke benefit, the favorable efficacy\u2013safety balance supports DOACs as a convenient and effective option for prolonged secondary prevention in patients at ongoing risk of recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/hpc.0000000000000417","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:00:29Z","timestamp":1770289229000},"page":"e0417","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Direct Oral Anticoagulants in Extended Venous Thromboembolism: A Placebo-Controlled Grade Assessed Meta-Analysis"],"prefix":"10.1097","volume":"25","author":[{"given":"Zaryab","family":"Bacha","sequence":"first","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khola","family":"Qazi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aizaz Anwar","family":"Khalid","sequence":"additional","affiliation":[{"name":"Department of Medicine, Peshawar Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefaf Ali","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Zafar","family":"Khan","sequence":"additional","affiliation":[{"name":"Health Department Khyber Pakhtunkhuwa, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munazza","family":"Sikandar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Sajjad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Saeed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Manchester University Hospitals and NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Akbar","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinza","family":"Siddique","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nishtar Medical University, Multan, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina Zia","family":"Rashid","sequence":"additional","affiliation":[{"name":"Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abdullah","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Shahzad","sequence":"additional","affiliation":[{"name":"Foundation University Medical College, Islamabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javeria","family":"Javed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad Ghanim","family":"Al-Badri","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"R1-20260522","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1016\/S0140-6736(16)30514-1","article-title":"Deep vein thrombosis and pulmonary embolism.","volume":"388","author":"Di Nisio","year":"2016","journal-title":"Lancet"},{"key":"R2-20260522","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1161\/CIRCOUTCOMES.110.958397","article-title":"Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism.","volume":"4","author":"Ng","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R3-20260522","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archinte.162.10.1144","article-title":"Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis.","volume":"162","author":"Kahn","year":"2002","journal-title":"Arch Intern Med"},{"key":"R4-20260522","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1056\/NEJMoa032274","article-title":"Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism.","volume":"350","author":"Pengo","year":"2004","journal-title":"N Engl J Med"},{"issue":"6 Suppl","key":"R5-20260522","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"R6-20260522","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions.","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"key":"R7-20260522","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-2003-44463","article-title":"Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors.","volume":"3","author":"Hylek","year":"2003","journal-title":"Semin Vasc Med"},{"key":"R8-20260522","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism.","volume":"363","author":"EINSTEIN Investigators, Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"R9-20260522","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism.","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"R10-20260522","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.","volume":"368","author":"Schulman","year":"2013","journal-title":"N Engl J Med"},{"key":"R11-20260522","doi-asserted-by":"crossref","first-page":"f5133","DOI":"10.1136\/bmj.f5133","article-title":"Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.","volume":"347","author":"Castellucci","year":"2013","journal-title":"BMJ"},{"key":"R12-20260522","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"R13-20260522","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R14-20260522","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMoa2509426","article-title":"Apixaban for extended treatment of provoked venous thromboembolism.","volume":"393","author":"Piazza","year":"2025","journal-title":"N Engl J Med"},{"key":"R15-20260522","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism.","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"key":"R16-20260522","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R17-20260522","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R18-20260522","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R19-20260522","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R20-20260522","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jclinepi.2015.12.006","article-title":"Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments.","volume":"74","author":"Santesso","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"R21-20260522","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/bloodadvances.2024015371","article-title":"Duration of primary\/secondary treatment to prevent recurrent venous thromboembolism: a systematic review and meta-analysis.","volume":"9","author":"Li","year":"2025","journal-title":"Blood Adv"},{"key":"R22-20260522","doi-asserted-by":"crossref","first-page":"e048619","DOI":"10.1136\/bmjopen-2021-048619","article-title":"Comparative efficacy and safety of oral anticoagulants for the treatment of venous thromboembolism in the patients with different renal functions: a systematic review, pairwise and network meta-analysis.","volume":"12","author":"Su","year":"2022","journal-title":"BMJ Open"},{"key":"R23-20260522","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/08998280.2025.2554467","article-title":"Reduced-dose versus full-dose direct oral anticoagulants in extended treatment of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials.","volume":"38","author":"Albukhari","year":"2025","journal-title":"Bayl Univ Med Cent Proc"},{"key":"R24-20260522","first-page":"725","article-title":"Extended treatment of venous thromboembolism with reduced-dose versus full-dose DOACs.","volume":"405","year":"2025","journal-title":"Lancet"},{"key":"R25-20260522","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jama.2014.10538","article-title":"Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis.","volume":"312","author":"Castellucci","year":"2014","journal-title":"JAMA"},{"key":"R26-20260522","first-page":"e2322012","article-title":"Clinical outcomes of direct oral anticoagulants vs warfarin for extended treatment of VTE.","volume":"6","author":"Lutsey","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R27-20260522","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"R28-20260522","first-page":"100713","article-title":"The relationship of direct oral anticoagulants with cancer risk: evidence from randomized controlled trials.","volume":"42","author":"Hicks","year":"2020","journal-title":"Blood Rev"},{"key":"R29-20260522","first-page":"245","article-title":"Safety profile of direct oral anticoagulants in long-term use: a systematic review.","volume":"51","author":"Bauersachs","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"R30-20260522","first-page":"1172","article-title":"Safety of long-term DOAC use: evidence from randomized controlled trials and meta-analyses.","volume":"19","author":"Bauersachs","year":"2021","journal-title":"J Thromb Haemost"}],"container-title":["Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T13:00:48Z","timestamp":1779454848000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/hpc.0000000000000417","relation":{},"ISSN":["1535-2811"],"issn-type":[{"value":"1535-2811","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}